LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

Inicio・Lista de Acciones・Editas Medicine Inc

Editas Medicine Inc

Cerrado

SectorSanidad

2.76 3.37

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

2.73

Máximo

2.76

Métricas clave
By Trading Economics
Ingresos	-19M -25M
Ventas	-22M 2.8M
BPA	-0.26
Margen de beneficios	-882.444
Empleados	87
EBITDA	-19M -25M

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 Meses	+139.13% upside

Dividendos
By Dow Jones
Próximas Ganancias	10 ago 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-52M 241M
Apertura anterior	-0.61
Cierre anterior	2.76

Noticias sobre sentimiento de mercado

By Acuity

50%

151 / 345 Clasificación en Healthcare

Editas Medicine Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

24 may 2026, 23:46 UTC

Charlas de Mercado

Pullback in Oil Prices Could Temper Inflation Expectations -- Market Talk

24 may 2026, 23:45 UTC

Charlas de Mercado

Gold, Silver Rise on Hopes for U.S.-Iran Deal -- Market Talk

24 may 2026, 23:42 UTC

Charlas de Mercado

Mineral Resources Bull More Positive Post Site Visit -- Market Talk

24 may 2026, 23:34 UTC

Charlas de Mercado

Oil Falls Amid Prospects for Reopening of Strait of Hormuz -- Market Talk

24 may 2026, 23:11 UTC

Charlas de Mercado

RBNZ Likely to Stand Pat But Watch for Dissent -- Market Talk

24 may 2026, 22:26 UTC

Adquisiciones, fusiones, absorciones

Beach Energy: La Bella 2 Will No Longer Be Drilled as Part of Equinox Campaign

24 may 2026, 22:25 UTC

Adquisiciones, fusiones, absorciones

Beach Energy: Implied Transaction Value of Around A$130 Million After Tax

24 may 2026, 22:25 UTC

Adquisiciones, fusiones, absorciones

Beach Energy: Royalty Payments Likely to Total Around A$140 Million Based on Resource Booking

24 may 2026, 22:24 UTC

Adquisiciones, fusiones, absorciones

Beach Energy to Get Production Royalty of A$3.75/GJ in Deal

24 may 2026, 22:24 UTC

Adquisiciones, fusiones, absorciones

Beach Energy to Get A$70 Million Cash Proceeds When Deal Completes

24 may 2026, 22:23 UTC

Adquisiciones, fusiones, absorciones

Beach Energy Says Deal Includes Artisan Natural-Gas Discovery

24 may 2026, 22:23 UTC

Adquisiciones, fusiones, absorciones

Beach Energy Sells 60% Operated Interest in VIC/L35 Block in Otway Basin

24 may 2026, 22:11 UTC

Charlas de Mercado

Oil Price Unlikely to Return to Pre-Conflict Levels This Year -- Market Talk

24 may 2026, 22:04 UTC

Charlas de Mercado

Oil Price Likely Lower, Equities Higher on Iran Deal Talks Progress -- Market Talk

23 may 2026, 08:20 UTC

Charlas de Mercado

Adquisiciones, fusiones, absorciones

Financial Services Roundup: Market Talk

23 may 2026, 08:20 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

22 may 2026, 21:10 UTC

Ganancias

These Stocks Are Today's Movers: Dell, Apple, IBM, Estée Lauder, Futu, Rocket Lab, Workday, and More -- Barrons.com

22 may 2026, 20:50 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

22 may 2026, 20:50 UTC

Charlas de Mercado

Adquisiciones, fusiones, absorciones

Financial Services Roundup: Market Talk

22 may 2026, 20:50 UTC

Charlas de Mercado

Auto & Transport Roundup: Market Talk

22 may 2026, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

22 may 2026, 19:47 UTC

Ganancias

Nvidia Has a Plan to Get the Stock Moving Again -- Barrons.com

22 may 2026, 19:17 UTC

Charlas de Mercado

U.S. Natural Gas Retreats As Weather Outlook Cools -- Market Talk

22 may 2026, 19:10 UTC

Charlas de Mercado

Oil Futures Edge Up Ahead of U.S. Long Weekend -- Market Talk

22 may 2026, 18:54 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

22 may 2026, 18:54 UTC

Charlas de Mercado

Kroger Seen Narrowing Pricing Gap Versus Walmart -- Market Talk

22 may 2026, 18:38 UTC

Charlas de Mercado

Canada's Population Slowdown Hits Demand for Consumer Companies -- Market Talk

22 may 2026, 18:35 UTC

Adquisiciones, fusiones, absorciones

IMAX Might Be Exploring a Sale. Who Could Be Buying. -- Barrons.com

22 may 2026, 18:09 UTC

Charlas de Mercado

Centralized Crypto Lending Slows in 1Q -- Market Talk

22 may 2026, 17:58 UTC

Charlas de Mercado

U.S. Oil Rig Count Shows Signs of Picking Up -- Market Talk

Comparación entre iguales

Cambio de precio

Editas Medicine Inc previsión

Precio Objetivo

By TipRanks

139.13% repunte

Estimación a 12 Meses

Media 6.6 USD 139.13%

Máximo 15 USD

Mínimo 4 USD

De acuerdo con 10 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Editas Medicine Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

10 ratings

Comprar

Mantener

Vender

De acuerdo con 10 analistas que ofrecen calificaciones bursátiles a para Editas Medicine Inc Dist en los últimos 3 meses.

Sentimiento

By Acuity

151 / 345 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Editas Medicine Inc

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; collaboration and nonexclusive license agreement with Genevant Sciences to develop Novel mRNA-LNP gene editing therapeuticsand strategic alliance and option agreement with Allergan Pharmaceuticals International Limited, as well as collaboration with Bristol Myers Squibb for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.